President Biden signed a new spending bill that excluded key healthcare provisions, including drug pricing and prior authorization reforms. The excluded provisions would have limited the number of patents pharmaceutical companies can apply to biologics, clarified ingredient differences in generic drugs, and disconnected pharmacy benefit managers’ revenue from drug prices in Medicare Part D. Advocacy groups criticized the omission, stating that it will delay relief for patients and continue high drug prices in the U.S. Additionally, the bill did not address declining reimbursement rates for Medicare or provide long-term extensions for Medicare telehealth flexibilities and the Acute Hospital Care at Home program.
Source link
Healthcare Leaders Slam Exclusion of Key Healthcare Provisions in Spending Package
